Sidoti Has Bullish Forecast for Kamada FY2026 Earnings

Posted by George Bondi on Aug 14th, 2026

Kamada Ltd. (NASDAQ:KMDA – Free Report) – Research analysts at Sidoti increased their FY2026 EPS estimates for shares of Kamada in a research report issued to clients and investors on Wednesday, August 12th. Sidoti analyst J. Sidoti now forecasts that the biotechnology company will post earnings per share of $0.46 for the year, up from their prior forecast of $0.43. The consensus estimate for Kamada’s current full-year earnings is $0.44 per share.

Kamada (NASDAQ:KMDA – Get Free Report) last posted its quarterly earnings results on Wednesday, August 12th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.11 by $0.05. Kamada had a net margin of 11.60% and a return on equity of 8.41%. The business had revenue of $54.92 million during the quarter, compared to analysts’ expectations of $50.84 million.

A number of other brokerages also recently commented on KMDA. Weiss Ratings downgraded Kamada from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, June 25th. Benchmark reaffirmed a “buy” rating on shares of Kamada in a research note on Tuesday, July 21st. Wall Street Zen cut Kamada from a “buy” rating to a “hold” rating in a research report on Saturday, May 23rd. Finally, William Blair set a $15.00 target price on shares of Kamada in a research note on Tuesday, July 21st. Three analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $13.00.

View Our Latest Research Report on KMDA

Kamada Stock Performance

Shares of KMDA stock opened at $7.26 on Friday. Kamada has a fifty-two week low of $6.50 and a fifty-two week high of $9.35. The firm has a market capitalization of $417.52 million, a PE ratio of 19.11, a P/E/G ratio of 0.63 and a beta of 0.86. The stock’s 50-day simple moving average is $7.22 and its 200-day simple moving average is $7.96.

Hedge Funds Weigh In On Kamada

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Barclays PLC grew its holdings in Kamada by 417.1% in the 4th quarter. Barclays PLC now owns 4,788 shares of the biotechnology company’s stock valued at $34,000 after buying an additional 3,862 shares in the last quarter. China Universal Asset Management Co. Ltd. acquired a new position in shares of Kamada during the 4th quarter valued at about $66,000. XTX Topco Ltd purchased a new stake in shares of Kamada in the fourth quarter valued at about $103,000. SIH Partners LLLP acquired a new stake in Kamada during the fourth quarter worth about $134,000. Finally, Quadrature Capital Ltd raised its stake in Kamada by 53.5% during the fourth quarter. Quadrature Capital Ltd now owns 21,889 shares of the biotechnology company’s stock worth $155,000 after purchasing an additional 7,627 shares during the period. Institutional investors and hedge funds own 20.38% of the company’s stock.

Kamada Company Profile

(Get Free Report)

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma‐derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.

Among Kamada’s marketed products is Glassia®, an alpha‐1 antitrypsin augmentation therapy approved by the U.S.